Biotech Values

[iwfal]

he said that Lucentis brings in $2 billion for DRY AMD, when in fact the label is for wet.

In the Rodman and Renshaw presentation he clearly said there were no (FDA) approved treatments for Dry AMD. He separately said that the dry AMD market is (potentially - given that there are no approved treatments for dry AMD) much larger than the wet AMD market - and in the wet AMD market Lucentis is doing $2B/Year.